Research Topics
| Vici VargheseSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitorsVici Varghese
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
J Acquir Immune Defic Syndr 52:309-15. 2009..Therefore, we sought to determine how often NNRTI-resistant mutations other than K103N occur as minority variants in plasma samples for which standard genotypic resistance testing detects K103N alone...- Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutationVici Varghese
Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America
PLoS ONE 5:e10992. 2010..Several lines of evidence suggest that K65R is more common in HIV-1 subtype C than subtype B viruses... - HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravirVici Varghese
Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
AIDS Res Hum Retroviruses 26:1323-6. 2010..However, none of the major INI-resistance mutations was found to be polymorphic in either study and there were no significant changes in the prevalence of any of the minor INI-resistance mutations... - Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibilityVici Varghese
Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Antimicrob Agents Chemother 53:2196-8. 2009..We report that Q145M and other Q145 mutations do not emerge with RT inhibitors nor decrease RT inhibitor susceptibility. Q145M should not, therefore, be considered an RT inhibitor resistance mutation... - Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vectorElizabeth C Reuman
Department of Medicine, Stanford University School of Medicine, Division of Infectious Diseases, 300 Pasteur Drive, Grant Building, Room S 146, Stanford, CA 94305, USA
Antimicrob Agents Chemother 54:934-6. 2010..Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants... - Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineMaya Balamane
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA
Antimicrob Agents Chemother 56:4522-4. 2012..Each virus in the panel has intermediate- or high-level resistance to all or three of the four most commonly used NNRTIs... - Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutationsYumi Mitsuya
Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
J Virol 82:10747-55. 2008.... - Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistanceFarbod Babrzadeh
Stanford Genome Technology Center, Stanford University, Stanford, CA 94305, USA
J Antimicrob Chemother 68:414-8. 2013..To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs...